Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Tophus Stories

2014-01-10 08:23:06

Acquisition is highlighted by KRYSTEXXA® (pegloticase), the only product approved for the treatment of refractory chronic gout GLENDALE, Wis., Jan. 10, 2014 /PRNewswire/ -- Crealta Pharmaceuticals LLC ("Crealta"), a new specialty pharmaceutical company, announced today the completion of the acquisition of substantially all of the assets of Savient Pharmaceuticals, Inc. ("Savient"). Crealta previously announced the winning of an auction for these assets, the signing of a definitive...

2013-06-12 08:28:51

-- Post-Marketing Data Focuses on Safety of KRYSTEXXA® and the Appropriate Actions Taken From Post-Approval Safety Surveillance BRIDGEWATER, N.J., June 12, 2013 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that ongoing KRYSTEXXA(® )(pegloticase) post-marketing surveillance data describing the long-term safety data for KRYSTEXXA will be presented at the 2013 EULAR Congress in Madrid, Spain June 12-15. The two posters describe a decrease in the...

2013-05-22 08:28:04

-- Video Released on Gout Awareness Day Aims to Dispel Outdated Perceptions BRIDGEWATER, N.J., May 22, 2013 /PRNewswire/ -- Jim Belushi, Savient Pharmaceuticals and patient advocacy group CreakyJoints have released a new online video to encourage candid discussion about gout, an age-old and often misunderstood condition. The actor and performer has suffered from gout for more than 15 years and is an advocate within the gout community who aims to raise awareness and encourages...

2012-11-13 08:34:58

BRIDGEWATER, N.J., Nov. 13, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced results from new post-hoc analyses of KRYSTEXXA(®) (pegloticase) pivotal Phase III and open-label extension trials that reinforced the health-related quality of life (HRQOL) benefits of KRYSTEXXA treatment in adult patients with refractory chronic gout (RCG), including tophus reduction outcomes. New data also demonstrated that guidance on measuring serum uric acid (sUA) levels as...

2012-11-12 08:24:46

BRIDGEWATER, N.J., Nov. 12, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that new data from an open-label extension (OLE) study published in the Annals of the Rheumatic Diseases reinforced the safety and efficacy profile of KRYSTEXXA(®) (pegloticase) treatment for refractory chronic gout (RCG) over the long-term. OLE data aligned with outcomes seen in the KRYSTEXXA pivotal Phase III clinical trials, with no new safety signals identified. Improvements...

2012-10-19 11:23:30

BRIDGEWATER, N.J. and DUBLIN, Oct. 19, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) and its wholly owned subsidiary, Savient Pharma Ireland Limited, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has completed its scientific assessment and has issued a positive opinion recommending approval of a marketing authorization in the European Union for KRYSTEXXA(®) (pegloticase) for the treatment of severe...

2012-09-20 02:28:30

BRIDGEWATER, N.J., Sept. 20, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that several abstracts related to KRYSTEXXA(®) (pegloticase) in the treatment of patients with Refractory Chronic Gout (RCG) will be presented at the 2012 ACR/ARHP Annual Meeting taking place in Washington D.C., from November 9-14, 2012. Full text of the following accepted abstracts can be accessed by visiting the American College of Rheumatology website at...

2012-07-02 02:22:45

EAST BRUNSWICK, N.J., July 2, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced a new publication showing that adult patients with refractory chronic gout (RCG) treated bi-weekly with KRYSTEXXA(®) (pegloticase) experienced statistically significant and clinically meaningful improvements in health-related quality of life (HRQOL), pain and physical function. The article confirms that chronic gout, especially refractory chronic gout, is associated with decline...

2012-06-05 18:22:47

EAST BRUNSWICK, N.J., June 6, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that new data presented in an oral session at the European League Against Rheumatism (EULAR) 2012 congress showed that patients with refractory chronic gout (RCG) who also suffer from chronic kidney disease (CKD) responded to treatment with KRYSTEXXA(®) (pegloticase) regardless of baseline CKD stage. CKD stage is assigned based upon level of kidney function as measured by...

2012-05-22 02:27:24

BRIDGEWATER, N.J., May 22, 2012 /PRNewswire/ -- An online survey conducted by Red Hot Mamas North America, Inc. found that women and their loved ones are significantly affected by very painful bouts of gout, which they consider to be chronic and severe. Respondents indicated that although the debilitating pain associated with the condition affects quality of life, many individuals are prescribed medications meant to control the condition which they are not taking. Red Hot...